A study on the effect of rare sugar syrup on blood glucose level : randomized, placebo-controlled, double blind cross-over trial
- Conditions
- Healthy adult and borderline
- Registration Number
- JPRN-UMIN000018120
- Lead Sponsor
- CPCC Co.,Ltd.
- Brief Summary
We investigated the effects of rare sugar syrup (RSS) on the blood glucose response. First, we determined the glycemic index (GI) of RSS in a randomized single-blind crossover study involving 10 healthy subjects (age32.5+/-1.8y), and found that its value was 49. Second, we examined the effects of RSS on the post-prandial glycemic response in a randomized placebo-control, double-blind crossover study involving 50 healthy subjects, some of whom had borderline diabetes (age47.1+/-1.4y). Sucrose, which contains the same amount of glucose as RSS, was used as a control. Sucrose and RSS were dissolved in 150 mL of coffee. Blood was collected at 6 time-points over 120 min. We found that RSS showed a significantly greater reduction in the 120-min AUC of both blood glucose and insulin compared to the control. This study demonstrated that RSS is a low GI sweetener that elicits a significantly lower glycemic response than sucrose in humans. A second study has been approved by the institutional ethics committee, and is registered in the clinical trial registration system UMIN-CTR (UMIN000018120). (J. Jpn. Soc. Nutr. Food Sci. 70:271-278(2017))
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1)These prescreened medicine. (2)These having Food for Specified Health Uses (FOSHU) and/or health food. (3)Subjects who have previous medical history and/or current medical history of serious diseases (e.g., diabetes, circulatory organ, liver, kidney, heart and/or digestive organ). (4)Pregnant women, lactating women, or women who want to get pregnant during the trial period (5)Heavy alcohol drinker. (6)Those that have extremely disheveled lifestyle and/or dietary habits. (7)Subjects who have previous medical history of drug and/or food allergy. (8)Subjects who have donated over 200 mL of blood and/or blood components within the last one month prior to the current study. (9)Subjects who have donated over 400 mL of blood and/or blood components within the last tree months prior to the current study. (10)Subjects who have donated over 400 mL of blood and/or blood components within the last four months prior to the current study. (11)Subjects who collected blood amount of blood sampling over 1200 mL within the last twelve months prior to the current study and this clinical trial's blood sampling. (12)Subjects who collected blood amount of blood sampling over 800 mL within the last twelve months prior to the current study and this clinical trial's blood sampling. (13)Subjects who have donated over 400 mL of blood and/or blood components within the last four months prior to the current study. (14)Subjects who have been determined ineligible by principal investigator or sub-investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method